Uterine Natural Killer (uNK) Cell Expression in Patients With Repeated ICSI Failures: A Multicenter Cohort Study
Launched by TANTA UNIVERSITY · Apr 29, 2021
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the role of a type of immune cell called uterine Natural Killer (uNK) cells in women who have experienced repeated failures with a fertility treatment known as ICSI (Intracytoplasmic Sperm Injection). The study aims to understand whether these uNK cells, which are important for implantation and early pregnancy, might be linked to why some women struggle to conceive despite undergoing multiple IVF treatments.
Women between the ages of 20 and 40 who have had more than two unsuccessful ICSI attempts may be eligible to participate. Those who have had prior surgeries on the uterus, have certain immune diseases, or have been tested for uNK cells before will not be included. Participants in the study can expect to undergo assessments related to their uNK cells and contribute to important research that could help improve fertility treatments for others facing similar challenges.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with IVF/ICSI failures more than 2 times
- • Age 20-40 years
- Exclusion Criteria:
- • prior uterine surgery
- • immunological disease
- • previous testing to uNK cells
About Tanta University
Tanta University is a prestigious academic institution located in Egypt, dedicated to advancing medical research and education. As a clinical trial sponsor, Tanta University leverages its extensive resources and expertise to conduct innovative research initiatives aimed at improving health outcomes. The university collaborates with a network of healthcare professionals, researchers, and institutions to facilitate rigorous clinical trials across various medical disciplines. Committed to ethical standards and scientific integrity, Tanta University strives to contribute to the global body of knowledge while fostering the next generation of medical professionals.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tanta, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials